ImmuCell: Dr. Joseph Crabb resigns as officer/employee; remains as consultant for Re-Tain FDA approvals

IMMUCELL CORP /DE/

Dr. Joseph H. Crabb resigned from all employee and officer roles effective Feb 11, 2022.
Crabb engaged as consultant/advisor to President; term through April 30, 2023 or FDA approval date.
Compensation: $70,000 payment due upon receipt of all FDA approvals for Re-Tain (Nisin) if still consulting.
Payment also triggered by change of control or sale/license of Nisin rights while consulting.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Joseph H. Crabb

Other Named Officer

ICCC · IMMUCELL CORP /DE/

Effective: 2022-02-11
Filed: February 11, 2022, 6:59 PM ET

On February 11, 2022, Dr. Joseph H. Crabb resigned from all positions he held at the Company, including without limitation as an employee and an officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Joseph H. Crabb resigned as other_named_officer at IMMUCELL CORP /DE/.

Action: resigned

Exact text from the filing

On February 11, 2022, Dr. Joseph H. Crabb resigned from all positions he held at the Company, including without limitation as an employee and an officer of the Company.

View on SEC.gov

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001213900-22-006916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.